Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ChemoCentryx Inc (NASDAQ:CCXI)

7.08
Delayed Data
As of Mar 23
 -0.08 / -1.12%
Today’s Change
1.92
Today|||52-Week Range
9.10
-4.32%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$344.8M

Company Description

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company. The company focuses on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. Its pipeline consist of CCX168 avacopan, CCX140:Diabetic Nephropathy, CCX872:Pancreatic Cancer, CCR1, CCR4, CCR5, CCR6, CXCR2, Vercirnon:IBD:crohn's disease, CCX507:IBD:Ulcerative Colitis and CCR6:Psoriasis. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.

Contact Information

ChemoCentryx, Inc.
850 Maude Avenue
Mountain View California 94043
P:(650) 210-2900
Investor Relations:

Employees

Shareholders

Individual stakeholders45.03%
Other institutional31.23%
Mutual fund holders17.89%

Top Executives

Thomas J. SchallChairman, President & Chief Executive Officer
Susan M. KanayaCFO, Secretary, Chief Administrative Officer & EVP
Pirow BekkerChief Medical Officer
Rajinder SinghSenior Vice President-Research
Markus J. CappelTreasurer & Chief Business Officer